Beyond Barriers Therapeutics is a biotech startup founded in 2015 with a mission to address the urgent need for effective treatment of traumatic brain injuries (TBI). With a staggering 230,000 people hospitalized annually in the U.S. due to TBI, the market demand for an innovative solution is evident. The company is leveraging promising research from the National Institutes of Health to develop a novel product focused on treating inflammation and cell death post-TBI, with the potential to significantly impact the $50 billion cost associated with these injuries. By utilizing a unique mechanism for drug delivery to the brain, Beyond Barriers Therapeutics aims to offer a groundbreaking approach to TBI treatment. Although specific details regarding their industries and headquarters are currently unavailable, the potential of their product to address a critical healthcare issue presents an opportunity for investment in a company aiming to make a tangible difference in a pressing medical field.
There is no investment information
No recent news or press coverage available for Beyond Barriers Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
